WOMENS HEALTH

Curriculum

21 Sections
54 Lessons
10 Weeks

Expand all sectionsCollapse all sections

ABORTION
2
- 1.1
  DEFINITION, PREVALENCE & ETIOLOGY
- 1.2
  TREATMENT PLAN
INFERTILITY
3
- 2.1
  DEFINITION, PREVALENCE & ETIOLOGY
- 2.2
  RISK FACTORS, INVESTIGATIONS & DIAGNOSIS & TREATMENT PLAN
- 2.3
  REFERRAL CRITERIA, IVF COMPLICATIONS, KEY INFORMATION
POLYCYSTIC OVARIAN SYNDROME (PCOS)
2
- 3.1
  DEFINITION, ETIOLOGY, RISK FACTORS & SIGNS & SYMPTOMS
- 3.2
  INVESTIGATIONS & DIAGNOSIS, TREATMENT PLAN, COMPLICATIONS & KEY INFORMATION
FEMALE PATTERN HAIR LOSS
4
- 4.1
  DEFINITION, PREVALENCE & ETIOLOGY
- 4.2
  RISK FACTORS, SIGNS & SYMPTOMS, FEATURES OF ALTERNATIVE AETIOLOGIES
- 4.3
  INVESTIGATIONS & DIAGNOSIS, TREATMENT PLAN
- 4.4
  PROGNOSIS, KEY INFORMATION & EXTRA’S
HIRSUTISM (EXCESSIVE HAIR GROWTH)
3
- 5.1
  DEFINITION, ETIOLOGY & RISK FACTORS
- 5.2
  DIFFERENTIALS
- 5.3
  INVESTIGATIONS, TREATMENT PLAN & KEY INFORMATION
FIBROIDS
3
- 6.1
  DEFINITION, PREVALENCE & ETIOLOGY
- 6.2
  RISK FACTORS, SIGNS & SYMPTOMS & INVESTIGATIONS & DIAGNOSIS
- 6.3
  TREATMENT PLAN, COMPLICATIONS, KEY INFORMATION & EXTRA’S
ENDOMETRIOSIS
3
- 7.1
  DEFINITION, PREVALENCE, RISK FACTORS
- 7.2
  SIGNS & SYMPTOMS, INVESTIGATIONS & DIAGNOSIS, TREATMENT PLAN
- 7.3
  KEY INFORMATION, EXTRA’S
OVARIAN CANCER
2
- 8.1
  DEFINITION, PREVALENCE & ETIOLOGY
- 8.2
  RISK FACTORS, SIGNS & SYMPTOMS & INVESTIGATIONS & DIAGNOSIS
CERVICAL CANCER & SCREENING
3
- 9.1
  DEFINITION, PREVALENCE & ETIOLOGY
- 9.2
  RISK FACTORS, SIGNS & SYMPTOMS, INVESTIGATIONS & DIAGNOSIS
- 9.3
  TREATMENT PLAN, PROGNOSIS, KEY INFORMATION & EXTRA’S
AMENORRHOEA
3
- 10.1
  DEFINITION, ETIOLOGY
- 10.2
  RISK FACTORS, SIGNS & SYMPTOMS
- 10.3
  INVESTIGATIONS, TREATMENT PLAN, KEY INFORMATION & EXTRA’S
MENORRHAGIA
3
- 11.1
  DEFINITION, PREVALENCE & ETIOLOGY
- 11.2
  RISK FACTORS, INVESTIGATIONS & DIAGNOSIS
- 11.3
  TREATMENT PLAN, REFERRAL CRITERIA, KEY INFORMATION & EXTRAS
DYSMENORRHOEA
3
- 12.1
  DEFINITION, ETIOLOGY & RISK FACTORS
- 12.2
  SIGNS & SYMPTOMS, INVESTIGATIONS & DIAGNOSIS, TREATMENT PLAN
- 12.3
  KEY INFORMATION
PRE-MENSTRUAL SYNDROME
2
- 13.1
  DEFINITION, RISK FACTORS, SIGNS & SYMPTOMS
- 13.2
  INVESTIGATIONS & DIAGNOSIS, TREATMENT PLAN, KEY INFORMATION
MENOPAUSE & HRT
4
- 14.1
  DEFINITION, PREVALENCE & ETIOLOGY
- 14.2
  IMPORTANT ASSOCIATED TYPES, SIGNS & SYMPTOMS, INVESTIGATIONS
- 14.3
  TREATMENT PLAN, PROGNOSIS
- 14.4
  KEY INFORMATION, EXTRA’S
POST-NATAL CARE
2
- 15.1
  DEFINITION, SIGNS & SYMPTOMS
- 15.2
  INVESTIGATIONS & DIAGNOSIS, TREATMENT PLAN
BREAST CANCER
2
- 16.1
  DEFINITION, PREVALENCE & ETIOLOGY
- 16.2
  RISK FACTORS, INVESTIGATIONS & DIAGNOSIS, TREATMENT PLAN
BREAST CANCER – SCREENING
2
- 17.1
  DEFINITION, PREVALENCE, ETIOLOGY
- 17.2
  RISK FACTORS, INVESTIGATIONS & DIAGNOSIS
TAMOXIFEN
2
- 18.1
  DEFINITION, ETIOLOGY, SIGNS & SYMPTOMS
- 18.2
  TREATMENT PLAN
BREAST - MASTITIS
3
- 19.1
  DEFINITION, PREVALENCE & ETIOLOGY
- 19.2
  RISK FACTORS, SIGNS & SYMPTOMS, INVESTIGATIONS & DIAGNOSIS
- 19.3
  TREATMENT PLAN, PROGNOSIS & KEY INFORMATION
BREAST PAIN
3
- 20.1
  DEFINITION, PREVALENCE & ETIOLOGY
- 20.2
  RISK FACTORS, SIGNS & SYMPTOMS, INVESTIGATIONS & DIAGNOSIS
- 20.3
  TREATMENT PLAN, PROGNOSIS, KEY INFORMATION
Flash Card
0

TREATMENT PLAN

TREATMENT PLAN
Indications:
• Oestrogen receptor-positive breast cancer
• Anovulatory infertility
• Primary prevention in moderate-high-risk breast cancer Contraindications:
• Pregnancy
• Breastfeeding
• High VTE risk (in primary prevention/infertility)
• Previous DVT
Key interactions:
• Anastrozole: contraindicated
• Warfarin: contraindicated if used for primary prevention
• Hormonal contraception: UKMEC4, Specialist discussion is needed if hormonal contraception is considered after 5 years cancer-free of breast cancer (UKMEC3) • HRT: avoid concurrent use Monitoring/Management:
• Stop 6 weeks before elective surgery
• Need effective contraception during and 2 months after treatment (Non-hormonal contraception preferred).